Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djae180 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Nadia Howlader und 7 weiteren Autor:innen. Beteiligte Einrichtung: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Surveillance Research Program, Division of Cancer Control and Population Sciences, NCI NIH HHS.
Abstract (Originalsprache)
The COVID-19 pandemic led to substantial declines in cancer incidence rates in 2020, likely because of disruptions in screening and diagnostic services. This study aimed to assess the impact of the pandemic on cancer incidence rates in the United States using 2021 incidence data from the Surveillance, Epidemiology, and End Results program. The analysis compared observed 2021 cancer incidence rates with expected prepandemic trends, evaluating changes by individual cancer site and stage. Although incidence overall and in many cancer sites the rates were close to prepandemic levels, they did not exhibit a recovery that incorporated the delayed diagnoses from 2020. There were exceptions, however, such as metastatic breast cancer, which showed significantly higher observed rates than expected (rate ratio = 1.09, 95% confidence interval = 1.04 to 1.13). Ongoing monitoring and targeted interventions are needed to address the long-term consequences of the COVID-19 pandemic on cancer care and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
- Information Management Services, Calverton, MD, USA.
ORCID-Profile: Nadia Howlader, Huann-Sheng Chen, Serban Negoita
Förderung
- Surveillance Research Program
- Division of Cancer Control and Population Sciences
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Howlader, N., Chen, H. S., Noone, A. M., Miller, D., Byrne, J., Negoita, S., Cronin, K. A., & Mariotto, A. B. (2025). Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae180
Vancouver
Howlader N, Chen HS, Noone AM, Miller D, Byrne J, Negoita S, et al. Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae180
BibTeX
@article{Howlader2025,
author = {Howlader, Nadia and Chen, Huann-Sheng and Noone, Anne-Michelle and Miller, Daniel and Byrne, Jeffry and Negoita, Serban and Cronin, Kathleen A and Mariotto, Angela B},
title = {Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djae180}
}
EUVIMED